Certara is transforming pediatric drug development with innovative modeling, simulation, and regulatory strategies. Our unique Pediatric MIDD approach integrates cutting-edge biosimulation with regulatory science, enabling the design of pediatric programs that meet global regulatory standards and ensure safe, effective medicines for children. With over 100 successful pediatric programs in our portfolio, we provide unmatched expertise in addressing challenges such as small populations, research burden, and physiological differences across age groups.
儿科药物开发
Advancing pediatric drug development with Certara
Innovative, evidence-based solutions for faster access to life-saving medicines for children.
Learn more about our Pediatric Drug Development Services
Comprehensive pediatric drug development support
Strategic planning
Create robust pediatric study plans (PSPs) and pediatric investigation plans (PIPs) tailored to regulatory requirements.
Innovative modeling
Leverage PK, PD, and disease progression models to optimize dosing and efficacy.
监管专业知识
Navigate complex pediatric regulatory landscapes with expert guidance.
Comprehensive services
End-to-end support, from juvenile toxicology to real-world evidence integration.
Certara’s unique approach to pediatric drug development
Explore our pediatric drug development solutions
临床药理学
Strategies tailored for pediatric populations.
定量药理学
Quantitative insights for informed pediatric trial designs.
法规事务咨询
Expert guidance for PIP and PSP submissions.
青少年毒理学
Ensuring the safety of pediatric therapies.
Real-world evidence
Data-driven insights from pediatric populations.
Meet the visionaries driving pediatric success
1 / 4
专家
Amy Cheung, PhD
Vice President, Certara Drug Development Solutions
Dr. Cheung leads pediatric pharmacometric strategies, with expertise in PK/PD modeling and regulatory planning.
建立联系
2 / 4
专家
Justin Hay, PhD
Senior Director, Clinical Pharmacology and Translational Medicine, Certara Drug Development Solutions
Dr. Hay has over 25 years of clinical pharmacology experience, previously working as a clinical pharmacology assessor of the MHRA (UK) and EMA.
建立联系
3 / 4
专家
Eva Berglund, PhD
Director, Clinical Pharmacology and Regulatory Strategy, Certara Drug Development Solutions
Dr. Berglund has over 12 years of experience working with all types of molecules in marketing applications, clinical trials and scientific advice procedures in the EMA.
建立联系
4 / 4
专家
Trevor Johnson, PhD
Principal Scientist
Dr. Johnson develops cutting-edge pediatric software for dose predictions and drug response analysis.
建立联系Discover more insights
查看全部Partner with Certara for pediatric drug development
Certara is your partner in overcoming pediatric drug development challenges and accelerating access to life-saving medicines for children. With advanced biosimulation tools, regulatory expertise, and a proven team, we deliver solutions that meet and exceed expectations.
Expertise in over 15 therapeutic areas.
Proven track record with more than 100 pediatric programs.
Industry-leading tools like Simcyp™ Pediatric PBPK Simulator.
下载Certara解决方案概览
Explore our comprehensive solutions
常见问题解答
What is the RACE for Children Act?
The RACE for Children Act mandates iPSP submissions for oncology drugs targeting pediatric cancers.
How does Certara ensure regulatory compliance?
Certara’s team provides expert guidance on PIP/PSP submissions and regulatory interactions with FDA and EMA.
What tools does Certara use in pediatric drug development?
The Simcyp™ Pediatric PBPK Simulator is a key tool used for modeling and predicting drug performance.
